10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Armistice Capital LLC

Armistice Capital LLC lowered its stake in 10x Genomics, Inc. (NASDAQ:TXG) by 2.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 154,482 shares of the company’s stock after selling 3,804 shares during the quarter. Armistice Capital LLC owned 0.13% of 10x Genomics worth $3,005,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TXG. Venrock Management VI LLC purchased a new stake in 10x Genomics during the 4th quarter worth approximately $117,894,000. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of 10x Genomics by 58.6% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,621,778 shares of the company’s stock worth $135,925,000 after purchasing an additional 1,338,248 shares in the last quarter. Vanguard Group Inc. raised its stake in 10x Genomics by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 9,101,536 shares of the company’s stock valued at $341,581,000 after purchasing an additional 90,204 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in 10x Genomics by 264.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 319,287 shares of the company’s stock valued at $11,983,000 after purchasing an additional 231,697 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in 10x Genomics by 604.9% during the 2nd quarter. SG Americas Securities LLC now owns 101,344 shares of the company’s stock worth $1,971,000 after purchasing an additional 86,967 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Price Performance

Shares of NASDAQ TXG opened at $22.30 on Friday. The company has a market cap of $2.69 billion, a price-to-earnings ratio of -10.00 and a beta of 1.85. The stock’s 50-day moving average is $21.31 and its two-hundred day moving average is $24.82. 10x Genomics, Inc. has a 1-year low of $15.28 and a 1-year high of $57.90.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.15. 10x Genomics had a negative net margin of 37.90% and a negative return on equity of 28.23%. The company had revenue of $153.10 million during the quarter, compared to analysts’ expectations of $150.90 million. Equities research analysts anticipate that 10x Genomics, Inc. will post -1.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on TXG shares. Jefferies Financial Group upgraded shares of 10x Genomics from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research report on Monday, July 22nd. UBS Group cut their price objective on shares of 10x Genomics from $30.00 to $25.00 and set a “neutral” rating for the company in a report on Tuesday, August 13th. The Goldman Sachs Group lowered their target price on 10x Genomics from $26.00 to $16.00 and set a “sell” rating on the stock in a report on Tuesday, July 9th. JPMorgan Chase & Co. cut 10x Genomics from an “overweight” rating to a “neutral” rating and cut their price target for the company from $40.00 to $20.00 in a report on Thursday, July 18th. Finally, Canaccord Genuity Group reduced their price objective on 10x Genomics from $50.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.60.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 6,749 shares of 10x Genomics stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $152,054.97. Following the completion of the sale, the chief executive officer now directly owns 882,467 shares of the company’s stock, valued at approximately $19,881,981.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other 10x Genomics news, insider Benjamin J. Hindson sold 4,351 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $98,028.03. Following the transaction, the insider now owns 345,704 shares of the company’s stock, valued at $7,788,711.12. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Serge Saxonov sold 6,749 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $152,054.97. Following the completion of the sale, the chief executive officer now directly owns 882,467 shares of the company’s stock, valued at $19,881,981.51. The disclosure for this sale can be found here. Insiders have sold a total of 14,061 shares of company stock worth $316,794 over the last ninety days. Corporate insiders own 10.03% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.